Vetera® GoldXP

Combination Vaccine for Horses


  • VETERA® GOLDXP is the industry's #1 vaccine1

  • VETERA® GOLDXP has been shown to be effective for the vaccination of healthy horses 4 months of age or older, including pregnant mares, against:

    • Eastern and western encephalomyelitis (EEE & WEE)

    • West nile virus (WNV)

    • Tetanus

    • Respiratory disease due to equine herpes virus types 1 and 4 (EHV-1 & EHV-4)

    • Equine influenza virus (EIV)

  • VETERA® GOLDXP has also been shown to be effective against viral shedding due to A2 EIV and against viremia, mortality, and neurological clinical disease due to WNV 

  • The VETERA® portfolio features a wide range of progressive choices and contains the most comprehensive 1 mL vaccine (VETERA® GOLDXP + VEE) on the US market

  • VETERA® was the first vaccine in the US updated to contain both Florida sublineage clade 1 and clade 2 EIV, as recommended by the Expert Surveillance Panel (OIE) on Equine Influenza and AAEP

Features & Benefits


  • Contains a combination of various antigens in one vaccine

    • Influenza

    • Herpesvirus types 1 and 4 (EHV-1 and EHV-4)

    • West Nile Virus (WNV)

    • Eastern and Western Equine Encephalomyelitis (EEE and WEE)

    • Tetanus

  • Contains Kentucky lineage (KY/95), Florida sublineage clade 1 (OH/03), and Florida sublineage clade 2 (RI/07) equine influenza strains

  • Contains EHV-1 and EHV-4

  • Includes a unique North American Equine E159™ WNV strain

  • Incorporates the Carbimmune® adjuvant formulation

  • Ultrafil® purification technology


  • 7-way protection in one vaccine

  • Carbimmune® adjuvant system allows a dual-phase antigen presentation to deliver both rapid and long-lasting immunity

  • Ultrafil® purification technology eliminates undesirable cellular components and extraneous protein to minimize the potential injection site reactions (such as heat, swelling, and inflammation)

  • At least 6-month duration of immunity against EIV (OH/03)

  • At least 12-month WNV duration of immunity

  • Safe for use in horses as young as 4 months of age, including pregnant mares

Dosage & Administration

Shake well before use. Using aseptic technique, inoculate horses intramuscularly (IM) with a 1 mL dose.


Administer a second 1mL dose intramuscularly in 3-4 weeks using a different injection site.


The need for annual booster vaccination has not been established for this product. Consultation with a veterinarian for revaccination frequency should be considered.

Safety Information


  • Store at at 35-46°F (2-8°C)

  • Do not freeze

  • Do not mix with other products

  • Do not vaccinate within 21 days before slaughter

  • Use entire contents when first opened


In case of anaphylactoid reaction, administer epinephrine. In case of human exposure, contact a physician.


  1. Ceesa vaccines data. July, 2021.

VETERA® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. ULTRAFIL® and CARBIMMUNE® are registered trademarks of Boehringer Ingelheim Animal Health USA, Inc. ©2021 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0104-2021